Michael Barbella, Managing Editor11.29.22
Conformis Inc.'s new Actera Hip System has made its official clinical debut.
The first procedure with the new system was performed at Ascension Saint Thomas Hospital in Nashville, Tenn., using a minimally invasive direct-anterior approach. “The Actera hip system is a great new option for hip reconstruction surgeons,” said William Kurtz, M.D., who conducted the surgery. “Conformis’ addition of a tri-taper stem design enables surgeons to treat a broader range of patient anatomies and the shorter length options offer easier access to the femur while maintaining the fixation and integrity required for long term success of the implant.”
The new system is currently rolling out to select U.S. sites, and the company anticipates the full commercial launch of Actera in mid-2023. Actera will feature several personalization options for surgeons to choose what best fits their patients, even for complex anatomies.
The Actera Hip System uses a cutting-edge tri-taper stem design, which features a range of sizes and angles derived from the company’s patient data analytics. This cementless hip stem component features a proximally coated titanium spray with a hydroxyapatite layer to encourage initial and long-term fixation.
“We are pleased with the initial interest and positive reception of our Actera Hip System, which is part of Conformis’ continued efforts to be at the forefront of design, technology and personalization in total joint replacement,” Conformis President/CEO Mark Augusti said. “This new addition to our portfolio allows us to expand our offering to surgeons treating patients in need of hip replacement surgery.”
Actera is available in variable collar lengths to avoid the overhang or stem subsidence that can occur when using implants with fixed collar lengths. In addition, the hip system has two head-center options in each size, enabling a more intuitive intraoperative experience.
Most significantly, this is a major building block for the future. Once Actera’s tri-taper stem design is combined with Conformis’ proprietary three-dimensional, data-driven personalized hip planning software, surgeons will be able to choose, pre-operatively, the best fit implant construct for their patients’ needs and their choice in surgical technique. The company believes this will result in a more efficient and streamlined operating room experience, a less invasive procedure, and a more stable fit for initial and long-term fixation.
“As with our Identity and Imprint knee replacement systems, Actera is a data-driven design derived from both Conformis’ industry leading database of thousands of patients’ anatomies and our advanced surgical planning experience,” Marketing Vice President James Paiva said. “This enables Conformis to continue to design and deliver the industry’s most comprehensive portfolio of personalized products and surgical planning for total joint replacement.”
Founded in 2004, Conformis is focused on advancing orthopedic patient care. Its product portfolio is designed to maximize surgeon and patient choice by offering fully personalized solutions through its Image-to-Implant Platinum Services Program as well as data-informed, standardized solutions that combine many benefits of personalization with the convenience and flexibility of an off-the-shelf system. Conformis’ sterile, just-in-time, Surgery-in-a-Box delivery system is available with all of its implants and personalized, single-use instruments. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.
The first procedure with the new system was performed at Ascension Saint Thomas Hospital in Nashville, Tenn., using a minimally invasive direct-anterior approach. “The Actera hip system is a great new option for hip reconstruction surgeons,” said William Kurtz, M.D., who conducted the surgery. “Conformis’ addition of a tri-taper stem design enables surgeons to treat a broader range of patient anatomies and the shorter length options offer easier access to the femur while maintaining the fixation and integrity required for long term success of the implant.”
The new system is currently rolling out to select U.S. sites, and the company anticipates the full commercial launch of Actera in mid-2023. Actera will feature several personalization options for surgeons to choose what best fits their patients, even for complex anatomies.
The Actera Hip System uses a cutting-edge tri-taper stem design, which features a range of sizes and angles derived from the company’s patient data analytics. This cementless hip stem component features a proximally coated titanium spray with a hydroxyapatite layer to encourage initial and long-term fixation.
“We are pleased with the initial interest and positive reception of our Actera Hip System, which is part of Conformis’ continued efforts to be at the forefront of design, technology and personalization in total joint replacement,” Conformis President/CEO Mark Augusti said. “This new addition to our portfolio allows us to expand our offering to surgeons treating patients in need of hip replacement surgery.”
Actera is available in variable collar lengths to avoid the overhang or stem subsidence that can occur when using implants with fixed collar lengths. In addition, the hip system has two head-center options in each size, enabling a more intuitive intraoperative experience.
Most significantly, this is a major building block for the future. Once Actera’s tri-taper stem design is combined with Conformis’ proprietary three-dimensional, data-driven personalized hip planning software, surgeons will be able to choose, pre-operatively, the best fit implant construct for their patients’ needs and their choice in surgical technique. The company believes this will result in a more efficient and streamlined operating room experience, a less invasive procedure, and a more stable fit for initial and long-term fixation.
“As with our Identity and Imprint knee replacement systems, Actera is a data-driven design derived from both Conformis’ industry leading database of thousands of patients’ anatomies and our advanced surgical planning experience,” Marketing Vice President James Paiva said. “This enables Conformis to continue to design and deliver the industry’s most comprehensive portfolio of personalized products and surgical planning for total joint replacement.”
Founded in 2004, Conformis is focused on advancing orthopedic patient care. Its product portfolio is designed to maximize surgeon and patient choice by offering fully personalized solutions through its Image-to-Implant Platinum Services Program as well as data-informed, standardized solutions that combine many benefits of personalization with the convenience and flexibility of an off-the-shelf system. Conformis’ sterile, just-in-time, Surgery-in-a-Box delivery system is available with all of its implants and personalized, single-use instruments. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.